ReviewJournal of thoracic disease2025
IgG4-related disease and pleural effusion: a systematic review.
Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paradigm shift in the diagnosis of tuberculous pleural effusion: impact of epidemiology.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory condition that rarely affects the pleura, with pleural effusion (PE) reported in only 4% of cases. The characteristics of PE in patients with IgG4-RD are unknown. The objectives of this systematic review were to document the histological and biochemical characteristics of PF and pleural tissue, assess its clinical course, and determine the most effective treatments for the management of PE. Methods: A PRISMA literature search was conducted for published articles describing the characteristics of PE in IgG4-RD and discussing the approach to PE in this setting. Results: A total of 46 articles [55 patients and 57 pleural fluid (PF) samples] were included. Median age was 66 years (range, 28-86 years), with a male/female ratio of 2.9:1. PE was predominantly right-sided or bilateral (81.3%) and usually occupied <2/3 of the hemithorax (78.9%). PF generally had a serous appearance (84.2%) and was an exudate in 94.6% of cases with predominance (≥50%) of mononucleated cells in 96% (24/25). A predominance of eosinophils (≥10%) was observed in 40% (4/10 cases). As many as 66.7% of patients presented values of adenosine deaminase (ADA) ≥35 U/L (18/27), pH values remained within normal range 7.35-7.45 (15.4%) in only two patients. Three patients had glucose values <60 mg/dL (12.5%) and the PF of two patients was a chylothorax. Pleural biopsy was consistent with diagnosis in 95.6% of cases (43/45). In total, 92.7% of patients (51/55) received treatment with corticosteroids, and 9 (17.6%) received immunosuppressants. Of the four cases left untreated, 2 underwent chest drainage. Clinical course was benign in 97.7% of patients (43/44; a patient died of unknown causes). Conclusions: Patients with IgG4-RD and PE are usually men over 50 years of age with small/moderate, right-sided or bilateral PE. PF is most commonly a lymphocytic exudate with elevated ADA values. Pleural biopsy can help establish diagnosis. Treatment with corticosteroids, combined or not with immunosuppressants, was usually effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.